Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

Beyond the Biopsy: Genetics as the On-Ramp to Better FSGS Cohorts

ET
30 Minutes
  • See a new cohorting opportunity in action. Using prior FSGS trials as the anchor, explore how genetics-plus-clinical logic opens a new approach to patient cohorting.
  • Watch a tiered cohort come together in minutes. Inside the kidney-native RenasightIQ™ environment, see how three tiers (genetic driver, clinical FSGS, and both) resolve a broad histologic label into higher-value subgroups.
  • Leave ready to do it yourself. Learn how self-serve access lets your team define and size glomerular cohorts on your own timeline.

Speakers

0

Darbey Raible, MS, CGC

Associate Director, Scientific Affairs
Natera

Darbey Raible is a certified genetic counselor with more than 15 years of experience in clinical and laboratory genetics. She served on the Natera team that developed the Renasight testing panel and has since supported the Organ Health business unit across clinical operations and medical affairs. Darbey currently serves as Associate Director of Data Science where she applies her clinical and laboratory genetics expertise to large-scale clinicogenomic data to inform disease characterization and precision drug development in kidney disease.

0

Bryce Powerman, MBA

Director of Business Development
Natera

Bryce Powerman is a healthcare professional, patient advocate, and survivor of DOCK8 deficiency, an ultra-rare primary immunodeficiency. Diagnosed at the National Institutes of Health (NIH) after a lengthy diagnostic odyssey, he eventually underwent a life-saving pediatric bone marrow transplant in a first-in-human trial. Bryce serves as the Director of Business Development at Natera, a leading genetic testing company in the renal space, where he champions early genetic testing and proactive education as critical tools for improving patient outcomes.

Register here!

Already registered? Click here to login.
Date/Time:
ET